Norges Bank’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-1,311,485
Closed -$1.01B 1084
2025
Q4
$1.01B Buy
+1,311,485
New +$891M 0.11% 161
2025
Q3
Sell
-1,196,479
Closed -$628M 1208
2025
Q2
$628M Buy
1,196,479
+67,955
+6% +$37.9M 0.08% 235
2025
Q1
$716M Buy
1,128,524
+2,591
+0.2% +$1.78M 0.1% 185
2024
Q4
$802M Buy
1,125,933
+3,827
+0.3% +$3.21M 0.11% 177
2024
Q3
$1.18B Sell
1,122,106
-4,842
-0.4% -$5.39M 0.16% 118
2024
Q2
$1.18B Buy
1,126,948
+22,674
+2% +$22M 0.18% 104
2024
Q1
$1.06B Buy
1,104,274
+42,471
+4% +$40.4M 0.17% 120
2023
Q4
$933M Buy
1,061,803
+3,051
+0.3% +$2.51M 0.16% 128
2023
Q3
$871M Buy
1,058,752
+12,397
+1% +$9.74M 0.18% 118
2023
Q2
$752M Buy
1,046,355
+45,242
+5% +$34.9M 0.15% 133
2023
Q1
$823M Buy
1,001,113
+34,646
+4% +$26.1M 0.18% 111
2022
Q4
$697M Buy
966,467
+59,854
+7% +$44.2M 0.17% 124
2022
Q3
$625M Buy
906,613
+24,303
+3% +$15.3M 0.17% 114
2022
Q2
$522M Sell
882,310
-105,326
-11% -$68.5M 0.13% 153
2022
Q1
$690M Buy
987,636
+22,945
+2% +$14.5M 0.15% 129
2021
Q4
$609M Sell
964,691
-15,695
-2% -$9.65M 0.13% 151
2021
Q3
$593M Sell
980,386
-56,321
-5% -$35M 0.13% 150
2021
Q2
$579M Buy
1,036,707
+56,299
+6% +$28.5M 0.13% 161
2021
Q1
$464M Sell
980,408
-68,709
-7% -$33.5M 0.11% 184
2020
Q4
$507M Sell
1,049,117
-122,982
-10% -$66.4M 0.12% 166
2020
Q3
$656M Sell
1,172,099
-81,428
-6% -$49.4M 0.17% 107
2020
Q2
$782M Buy
1,253,527
+433,272
+53% +$246M 0.23% 75
2020
Q1
$401M Buy
820,255
+3,375
+0.4% +$1.39M 0.14% 140
2019
Q4
$307M Hold
816,880
0.09% 220
2019
Q3
$227M Hold
816,880
0.07% 268
2019
Q2
$256M Buy
816,880
+16,098
+2% +$5.36M 0.08% 246
2019
Q1
$329M Buy
800,782
+17,765
+2% +$7.32M 0.11% 182
2018
Q4
$292M Hold
783,017
0.11% 185
2018
Q3
$316M Sell
783,017
-47,021
-6% -$17.9M 0.1% 184
2018
Q2
$286M Buy
830,038
+5,079
+0.6% +$1.59M 0.1% 209
2018
Q1
$284M Buy
824,959
+29,491
+4% +$10.3M 0.1% 195
2017
Q4
$299M Buy
795,468
+38,756
+5% +$15.7M 0.11% 192
2017
Q3
$338M Sell
756,712
-19,657
-3% -$9.35M 0.13% 163
2017
Q2
$381M Sell
776,369
-8,024
-1% -$3.51M 0.15% 131
2017
Q1
$304M Sell
784,393
-9,850
-1% -$3.65M 0.12% 164
2016
Q4
$292M Sell
794,243
-1,291
-0.2% -$491K 0.13% 164
2016
Q3
$305M Buy
795,534
+83,194
+12% +$33.4M 0.14% 132
2016
Q2
$249M Buy
712,340
+13,745
+2% +$5.29M 0.12% 171
2016
Q1
$252M Sell
698,595
-15,499
-2% -$6.39M 0.12% 160
2015
Q4
$388M Sell
714,094
-37,296
-5% -$20.2M 0.19% 102
2015
Q3
$350M Buy
751,390
+14,939
+2% +$8.02M 0.18% 107
2015
Q2
$376M Buy
736,451
+18,748
+3% +$9.15M 0.19% 107
2015
Q1
$324M Buy
717,703
+28,635
+4% +$12.1M 0.16% 126
2014
Q4
$283M Buy
689,068
+16,645
+2% +$6.55M 0.14% 135
2014
Q3
$242M Sell
672,423
-622,423
-48% -$209M 0.13% 149
2014
Q2
$366M Buy
1,294,846
+652,285
+102% +$193M 0.1% 203
2014
Q1
$193M Buy
642,561
+9,148
+1% +$2.82M 0.11% 184
2013
Q4
$174M Sell
633,413
-55,619
-8% -$16M 0.1% 200
2013
Q3
$216M Buy
689,032
+42,596
+7% +$11.2M 0.13% 158
2013
Q2
$145M Buy
+646,436
New +$151M 0.09% 224

Other funds holding REGN

Norges Bank's REGN Position: Q1 2026 in Review

Norges Bank sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 1,311,485 shares — an estimated $1.01B sold.

Norges Bank first reported a position in REGN in Q2 2013 and held it in 50 quarters. The position peaked at $1.18B in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Norges Bank reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Norges Bank sold 1,311,485 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $1.01B.
  • Norges Bank first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 50 quarters.
  • Norges Bank's Regeneron Pharmaceuticals position peaked at $1.18B in Q2 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Norges Bank's 13F filing for Q1 2026.